| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $131.2M | — |
| R&D Expense | $227.7M | +74.5% |
| SG&A Expense | $115.5M | +52.8% |
| Operating Income | -$217.3M | -5.4% |
| Income Tax | $7.1M | — |
| Net Income | -$95.5M | +49.5% |
| EPS (Basic) | -$1.02 | +57.0% |
| EPS (Diluted) | -$1.02 | +57.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $125.0M | -45.9% |
| Short-term Investments | $406.8M | +200.0% |
| Accounts Receivable | $13.9M | — |
| Inventory | $3.3M | — |
| Current Assets | $562.3M | +49.8% |
| Total Assets | $582.8M | +55.0% |
| Current Liabilities | $73.5M | +148.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$78.1M | +46.8% |
| Capital Expenditures | $2.2M | +868.3% |
| Investing Cash Flow | -$231.0M | -279.9% |
| Financing Cash Flow | $203.3M | +24.0% |
| Free Cash Flow | -$80.3M | +45.4% |
| Total Liabilities |
| $80.0M |
| +171.2% |
| Stockholders' Equity | $502.8M | +45.1% |